Amid rising antimicrobial resistance (AMR) worldwide, the Union Ministry of Health and Family Welfare has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials under central regulatory oversight.The amendment seeks to include ‘antimicrobials’ in the definition of ‘New Drug’ under Rule 2(1)(w)(v). Manufacturers would need central approval before applying for a manufacturing licence from state authorities."The proposal is intended to serve as an additional regulatory safeguard against antimicrobial resistance (AMR) by strengthening oversight of antimicrobial products and ensuring appropriate scrutiny of their quality, safety and efficacy before the grant of new manufacturing licences," the Ministry said.AMR occurs when bacteria, viruses, fungi and parasites evolve and no longer respond to medicines designed to treat infections. This makes infections harder to treat, increases the risk of severe illness and death, and can complicate medical procedures such as surgery and cancer treatment.Addressing the World Antimicrobial Resistance (AMR) Awareness Week 2026, Union Health Secretary Punya Salila Srivastava described AMR as one of the most serious public health challenges. She warned that misuse and overuse of antimicrobials could make even common infections difficult to treat and threaten decades of medical progress.Also read: Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHOWhat Does The Proposed Amendment Say?The Ministry proposed the amendment through draft Gazette Notification G.S.R. 983 (E), dated November 6.Manufacturers would need permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the concerned State Licensing Authority (SLA).Existing manufacturing licences will remain valid, and holders will not need to reapply for permission.The measure is expected to strengthen central oversight and help ensure the quality, safety and efficacy of antimicrobial products, the Ministry said.Why Does India Want To Tighten Antimicrobial Regulation?Read More: ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?The proposal follows concerns that antimicrobial manufacturing licences are being granted without adequate regulatory scrutiny, including bioavailability/bioequivalence (BA/BE) and stability studies.The absence of these assessments may affect product quality, safety and efficacy. Substandard or ineffective antimicrobials can contribute to AMR and pose risks to patient safety."The measure is part of the Government's broader efforts to promote the responsible use of antimicrobials, safeguard patient safety and address the growing public health challenge of AMR," the Ministry said.The amendment remains at the draft stage. The Ministry has invited objections and suggestions from stakeholders and the public before finalisation.Separate Licences For Bulk Drug SalesIn addition, the Ministry has proposed amendments to the Drugs Rules, 1945, to introduce separate application and licence forms for the wholesale sale of bulk drugs, including active and inactive bulk substances.Currently, a common licence covers the wholesale sale of both formulations and bulk drugs.The proposed framework would allow more focused oversight of bulk drug sales and improve accountability in the pharmaceutical supply chain, the Ministry said.Licences would specify the categories of bulk drugs handled by wholesalers, including those covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Bulk drug sales would also require the personal supervision of a competent person.